Business
Mesoblast (ASX:MSB) share price soars 14% on clinical trial results
The Mesoblast Limited (ASX: MSB) share price rocketed on news that the company’s drug, rexlemestrocel-L, is showing promising signs.
The Mesoblast share price closed today’s trade 14.29% higher at $2.56 per share. Notably, today is the highest its shares have been since the failure of remestemcel-L in treating COVID-19 patients was announced in late December.
Why is the Mesoblast share price soaring?
Mesoblast announced that a single dose of its drug rexlemestrocel-L provides a reduction in heart attacks, strokes and cardiac death in patients with chronic heart failure.
The results come from its landmark, randomised controlled phase 3 trial with 537 patients. Of the patients, who all had chronic heart failure, some received…
-
Noosa News20 hours agoLaidley e-scooter death: Tragic new details after Summah Richards killed in freak accident
-
General21 hours agoMinjee Lee rallies after third-round meltdown to share fifth place at LA Championship
-
General15 hours agoUkraine says Russia has ramped up attacks despite ‘Easter truce’
-
General14 hours agoPope Francis appears Easter Sunday to deliver blessing as recovery continues